1
Opinion article
Why do biosimilar medicines matter to the Economy?
Biosimilar medicines, despite being relatively unknown, have a great economic impact and are linked to innovation, competition, regulation, incentives and efficiency of public spending. In this brief article published on the FUNCAS (Savings Banks Foundation) blog, the economist and emeritus professor at the Carlos III University, Félix Lobo, reviews some of the reference documents on biosimilars published in recent years. years where the role of biosimilars in the Health Economy is delved into.
Lobo F. FUNCAS
https://blog.funcas.es/por-que-los-medicamentos-biosimilares-importan-a-la-economia/
2
video tip
Biosimilars in Crohn's disease and ulcerative colitis
The fourth video within the 2nd season of the YouTube video advice channel on “Biosimilars and Pharmacy”. In this case, the biosimilars used for Crohn's disease and ulcerative colitis are addressed: adalimumab and infliximab. The indications, routes of administration and different devices currently available for patients with this chronic inflammatory bowel disease are described.
CGCOF, Medicine Television and BioSim
https://www.youtube.com/watch?v=2SJmLzxiyKk
3
Reports
Monitoring the consumption of biosimilar medicines in Italy
The AIFA, Italian Medicines Agency, has published updated reports on the monitoring of biosimilar medicines in Italy (until May 2023). In addition to consumption and spending trends and regional variability, two more analyzes are presented on the evolution of prices in the different distribution channels as well as on the consumption trend of intravenous and subcutaneous formulations, where available.
AIFA
https://www.aifa.gov.it/en/monitoraggio-consumi-e-spesa-biosimilari
4
Press release
Comesaña highlights the pharmacological advances that are being produced in the treatment of rheumatic diseases
A press release from the Xunta de Galicia on the statements of the Health Minister, Julio García Comesaña, at the conference held at the Álvaro Cunqueiro Hospital, focused on therapies and treatments for rheumatic diseases. He highlighted the pharmacological advances in this field and advocated collaboration between professionals, patients and associations to improve the quality of life of those affected. The Xunta de Galicia promotes a quality and sustainable healthcare system, supporting the use of biosimilar medicines for the treatment of rheumatic diseases. These drugs, obtained through biotechnology, meet high quality and safety standards, and the Galician Health Service adapts quickly to therapeutic innovation.
Xunta de Galicia
5
ADIEX
Biosimilars in Oncology, what are they and what do they provide to patients?
The Spanish Society of Medical Oncology (SEOM) and the Spanish Association of Biosimilar Medicines (BioSim) have prepared a video on biosimilars for patients titled “Biosimilars in oncology: What are they and what do they provide for patients?” within the framework of an agreement signed between both entities. The video explains in an educational way what biosimilar medicines are, that the variability, intrinsic to biological medicines, is controlled and does not compromise either efficacy or safety. It is also remembered that these medicines contribute to the sustainability of the SNS.